CRISPR Therapeutics AG (NASDAQ: CRSP) on Monday, soared 3.40% from the previous trading day, before settling in for the closing price of $41.22. Within the past 52 weeks, CRSP’s price has moved between $36.52 and $74.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 31550.17%. The company achieved an average annual earnings per share of -10.94%. With a float of $82.08 million, this company’s outstanding shares have now reached $85.74 million.
Considering the fact that the conglomerate employs 393 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 4.30%, while institutional ownership is 69.36%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.94% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 22.07 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 97.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.23 in the next quarter and is forecasted to reach -4.05 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Compared to the last year’s volume of 2.13 million, its volume of 1.44 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 29.92%. Additionally, its Average True Range was 2.37.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 27.05%, which indicates a significant decrease from 39.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.07% in the past 14 days, which was lower than the 58.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $42.93, while its 200-day Moving Average is $48.18. Nevertheless, the first resistance level for the watch stands at $42.93 in the near term. At $43.25, the stock is likely to face the second major resistance level. The third major resistance level sits at $43.77. If the price goes on to break the first support level at $42.09, it is likely to go to the next support level at $41.57. Now, if the price goes above the second support level, the third support stands at $41.25.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
Market capitalization of the company is 3.66 billion based on 85,774K outstanding shares. Right now, sales total 37,310 K and income totals -366,250 K. The company made 35,690 K in profit during its latest quarter, and -37,310 K in sales during its previous quarter.
